Parnax Lab Limited

BSE:506128 Stock Report

Market Cap: ₹2.0b

Parnax Lab Past Earnings Performance

Past criteria checks 4/6

Parnax Lab has been growing earnings at an average annual rate of 56.1%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 18.3% per year. Parnax Lab's return on equity is 15%, and it has net margins of 6%.

Key information

56.1%

Earnings growth rate

53.0%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate18.3%
Return on equity15.0%
Net Margin6.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Parnax Lab makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:506128 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,9591182560
30 Jun 241,9011032450
31 Mar 241,888962450
31 Dec 231,832882350
30 Sep 231,791982290
30 Jun 231,7961002110
31 Mar 231,676862110
31 Dec 221,746702030
30 Sep 221,785842010
30 Jun 221,711921830
31 Mar 221,630821860
31 Dec 211,362531790
30 Sep 211,10491670
30 Jun 211,00841480
31 Mar 21901-41470
31 Dec 2092821470
30 Sep 20934-81470
30 Jun 20923-281470
31 Mar 20955-291560
31 Dec 19920-231430
30 Sep 19903-111380
30 Jun 191,085271370
31 Mar 191,100331460
31 Dec 181,122261360
30 Sep 181,140291330
30 Jun 181,00221220
31 Mar 181,064111190
31 Dec 171,055311110
30 Sep 171,066411060
30 Jun 171,024361020
31 Mar 1794837960
31 Dec 1692437960
30 Sep 1683129900
30 Jun 1676733840
31 Mar 1671225800
31 Dec 15784301140
30 Sep 15896381150
30 Jun 1597842760
31 Mar 151,03043850
31 Dec 14984341170
30 Sep 14881241150
30 Jun 1477821720
31 Mar 14686251080
31 Dec 1361931630

Quality Earnings: 506128 has high quality earnings.

Growing Profit Margin: 506128's current net profit margins (6%) are higher than last year (5.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 506128 has become profitable over the past 5 years, growing earnings by 56.1% per year.

Accelerating Growth: 506128's earnings growth over the past year (20.7%) is below its 5-year average (56.1% per year).

Earnings vs Industry: 506128 earnings growth over the past year (20.7%) exceeded the Pharmaceuticals industry 20.4%.

Return on Equity

High ROE: 506128's Return on Equity (15%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 23:50
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Parnax Lab Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vinayak M.FirstCall Research